La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2016 BIO CEO & Investor Conference
January 29 2016 - 08:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or
La Jolla), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced that the Company
will provide a corporate overview at the 2016 BIO CEO &
Investor Conference taking place February 8–9 in New York City.
2016 BIO CEO & Investor Conference
Presentation Details
Date: Monday, February 8, 2016 Time:
3:30 p.m. Eastern Time Location: Conrad Room @ Waldorf Astoria
Hotel New York Webcast:
LJPC Webcast Link
A live webcast of the presentation will also be available in the
Investor Relations section of La Jolla’s website at www.ljpc.com. A
replay of the presentation will be available on La Jolla’s website
for 30 days following the event.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
several product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension. LJPC-401 is La
Jolla’s novel formulation of hepcidin for the potential treatment
of conditions characterized by iron overload, such as hereditary
hemochromatosis, beta thalassemia and sickle cell disease.
LJPC-30Sa and LJPC-30Sb are Jolla’s next-generation gentamicin
derivatives for the potential treatment of serious bacterial
infections and rare genetic disorders, such as cystic fibrosis and
Duchenne muscular dystrophy. For more information on La Jolla,
please visit www.ljpc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160129005233/en/
La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D.,
Ph.D.President & Chief Executive Officer(858)
207-4264gtidmarsh@ljpc.comorDennis M. MulroyChief Financial
Officer(858) 433-6839dmulroy@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Feb 2024 to Mar 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Mar 2023 to Mar 2024